ABSTRACT
Literature is limited comparing induction immunosuppression in pediatric liver transplant (LTx) recipients. This is a single-center, retrospective cohort study of primary pediatric liver transplants at our center between 2005 and 2016 who received either basiliximab (BSX) or rabbit anti-thymocyte globulin (rATG) induction. Maintenance immunosuppression consisted of tacrolimus ± a corticosteroid taper. Exclusions included receipt of an ABO-incompatible graft, retransplantation, and multi-organ transplantation. Primary outcomes were incidence of treated biopsy-proven acute rejection (tBPAR) and PTLD within the first year and infections within 90 days of LTx. Secondary outcomes included graft and patient survival, time to first tBPAR, and incidence of steroid-resistant rejection (SRR) within the first year post-LTx. A total of 136 patients were included in the final analysis of which 57 patients (42%) received BSX induction. Patients who received rATG induction with or without a 2-week corticosteroid taper experienced significantly more tBPAR compared to those who received BSX induction with a 6-month corticosteroid taper (55.7% vs 33.3%, P = .01). There were no differences in the incidence of PTLD, infections, SRR, graft or patient survival, or time to first tBPAR between the two groups. Induction with rATG either with or without a short corticosteroid taper was associated with significantly more tBPAR in primary pediatric LTx recipients when compared to BSX induction with a prolonged corticosteroid taper in the setting of maintenance immunosuppression with tacrolimus.
Subject(s)
Antilymphocyte Serum/therapeutic use , Basiliximab/therapeutic use , Immunosuppression Therapy/methods , Immunosuppressive Agents/therapeutic use , Liver Transplantation , Adolescent , Child , Child, Preschool , Cohort Studies , Female , Humans , Infant , Male , Retrospective Studies , Treatment OutcomeABSTRACT
OBJECTIVES: To determine medication use patterns and associated health outcomes in Chinese individuals with diabetes, hypertension or hyperlipidaemia. METHODS: This community-based cross-sectional study was done in a north China city of 300 000 people. Participants were recruited by poster and phone call through Community Health Centres. Data were collected on 638 Chinese individuals. Interviews were done to screen for disease and health behaviours. Fasting blood was collected and analyzed. KEY FINDINGS: Participants' average age was 52 years. Self-reported prevalence of type 2 diabetes, hypertension and hyperlipidaemia was 9.6, 29.9 and 20.5% respectively. Medication adherence was found among 88, 60 and 81.5% of individuals with diabetes, hypertension and hyperlipidaemia respectively. Treatment success, as defined by medication adherence and treatment to goal was achieved by 21, 23 and 10% of diabetic, hypertensive and hyperlipidaemic patients. CONCLUSIONS: A large proportion of individuals with chronic disease in this China-based study were not being successfully treated, putting them at high risk for poor health outcomes. In this urban China setting, healthcare services need to be strengthened in order to achieve better treatment outcomes among chronic disease patients. It is recommended that community pharmacists contribute to improving these outcomes through participation in patient education, medication reconciliation and disease state management.
